Skip to main content

Table 1 Clinical characteristics of the studied patient

From: Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series

Case no.

1

2

3

4

5

Mean ± SD

OD

OS

OD1

OS

OD

OS

OD

OS

OD2

OS

Postconceptional age at birth (weeks)

24

24

31

31

31

31

32

32

29

29

29.4 ± 3.2

Birth weight (grams)

1040

1040

1480

1480

1300

1300

1700

1700

1100

1100

1324.0 ± 272.5

Zone of ROP

2

2

1

1

2

2

2

2

2

2

Stage of ROP

3

3

3

3

3

3

3

3

3

3

Plus disease

No

Yes

Yes

Yes

No

Yes

Yes

No

Yes

Yes

 

Vitreous changes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Post-conceptional age at IVB injection (weeks)

37

37

40

40

40

40

38

39

43

43

39.8 ± 2.2

Time of starting regression after IVB injection (weeks)

4

4

2

2

4

4

2

2

3

3

3.0 ± 1.1

Presentation of the initial

6

8

10.5

7.5

9

12

8

9

4

8.2 ± 2.3

Vitreous changes (weeks After injection) last follow up (weeks)

69

69

65

65

59

59

59

59

56

56

61.6 ± 5.3

  1. 1Three weπeks after IVB, localized TRD developed at ridge site that resolved 4.5 weeks afterward
  2. 2Seven weeks after IVB, a localized preretinal hemorrhage was observed at the posterior border of the temporal ridge which resolved in 2 weeks